Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00264082

Enrollment

Registered

2005-12-12

Start date

2004-09-30

Completion date

Unknown

Last updated

2017-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to breast cancer. Tartrate-resistant acid phosphatase (TRAP) is a protein released into the blood stream as a result of bone destruction caused by metastasis of breast cancer to the bone. Bone destruction causes pain and bone fractures. This study will measure TRAP levels in serum taken from breast cancer patients to see if TRAP levels will be able to predict the effect of Zometa® treatment on bone destruction, pain and bone fractures.

Interventions

DRUGZometa(drug)

Study design

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologic or cytologic documentation of breast cancer. 2. Stage IV Breast Cancer Patients with bone metastasis for whom Zometa treatment will be initiated. 3. Age \> 18 4. Written informed consent prior to study entry 5. Patients may be currently receiving hormone therapy, chemotherapy and/or radiation therapy to the primary tumor. 6. Life expectancy of at least 6 months. 7. We will include patients who have had previous or current radiation therapy to breast

Exclusion criteria

1. Concurrent malignancy with a second primary 2. Stage I, Stage II and Stage III 3. ECOG Performance Status 3 or 4. 4. Renal Failure - serum creatinine \>2.O mg/dL at screening 5. AST or ALT \> ULN X 3. at screening 6. Bilirubin \> 3.0 mg/dL at screening 7. Pregnant women 8. Prior or current bisphosphonate therapy 9. Any skeletal related event due to malignancy prior to study enrollment. 10. Patients with osteoporotic fractures prior to study enrollment. 11. Allergy to bisphosphonates 12. Any radiation therapy for the treatment of bone metastases \<4 weeks prior to study start. 13. Any chronic medical condition which would preclude performance or adherence to protocol requirements 14. Inability to provide informed consent \-

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026